TJThisuri Jayawardena

Thisuri Jayawardena

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Thisuri Jayawardena has a total of 32 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Rationalising Hepatocellular Carcinoma Screening in Chronic Hepatitis B: Evaluation of Predictive Scores in an Australian Cohort

    by Thisuri Jayawardena, Zein Salim, Luis Calzadilla Bertot, Joanne Bunney, Nicolas Demasi, Joanne Vallve, Leon Adams, Gary Jeffrey, David Speers, Gerry MacQuillan, et al.

    Background and Aims: Several predictive scores have been developed internationally to rationalise hepatocellular carcinoma screening in patients with chronic hepatitis B. This study evaluated the performance of these scores in a large Australian cohort. Methods: A retrospective analysis was undertaken on patients with chronic hepatitis B attending two tertiary hospitals from 1st January 2017 to 30th June 2023. Predictive scores were calculated at baseline and patients were followed for the development of hepatocellular carcinoma. Results: A total of 1080 patients were included. The average age was 48 years, 43% were female, 91% were non‐cirrhotic, and 51% received antivirals. Most patients (62%) were of Asian ethnicity, 13% African, and 9% Caucasian. Twenty‐one patients (1.9%) developed hepatocellular carcinoma during a median follow‐up of 5.2 years. The calculated sensitivity was 90.5% for PAGE‐B and modified PAGE‐B, and 42.9% for REACH‐B. Positive predictive values were below 4%, and negative predictive values exceeded 98% for all scores. The time‐dependent area under the curve at 5 years for PAGE‐B, modified PAGE‐B, and REACH‐B were 0.74, 0.80, and 0.68 respectively. The 5‐year cumulative incidence of hepatocellular carcinoma for patients with low, intermediate, and high PAGE‐B scores was 0.33%, 2.1% and 4.9% respectively (log‐rank, p < 0.001) and for modified PAGE‐B was 0.44%, 1.0% and 7.1% respectively ( p < 0.001). REACH‐B was unable to accurately stratify hepatocellular carcinoma risk ( p = 0.19). Conclusions: In our Australian cohort of diverse ethnicity, cirrhosis and treatment status, both PAGE‐B and modified PAGE‐B scores performed well with respect to hepatocellular carcinoma risk stratification and identifying low‐risk patients who may safely avoid screening.


  • Optimising the structure of outpatient clinic letters: insights from a survey of general practitioners and hospital doctors

    by Thisuri Jayawardena, Cory Lei, Katie McLeod, Aron Chakera

    Outpatient letters are an essential communication tool in healthcare. Yet doctors receive little training on letter writing and what details recipients consider important. We surveyed 106 hospital doctors and 63 general practitioners (GPs), identifying differences in each group's preferences; GPs preferred more structured, detailed letters. Opportunities for feedback, formal templates and advanced software systems can improve communication in outpatient clinics.


  • Successful Liver Retransplantation in a Patient With Disseminated Aspergillosis and Nocardiosis: A Case Report

    by Thisuri Jayawardena, Chloe Attree, Sarah Cole, Siong Hui, Bryon Jaques, Gerry MacQuillan, Briohny Smith, Michael Wallace, George Garas, Leon Adams, et al.


  • Open Access

    Antibiotic administration via indwelling peritoneal catheter to treat infected malignant ascites

    by Thisuri Jayawardena, Sona Vekaria, Sophie Krivinskas, Calvinjit Sidhu, Aron Chakera, Y. C. Gary Lee

    Indwelling pleural catheter is an established management for malignant pleural effusions. Extending its use to patients with malignant ascites by insertion of a catheter intraperitoneally enables regular outpatient drainage and improves quality‐of‐life. However, indwelling pleural/peritoneal catheter (IPC/IPeC) is associated with catheter‐related infections, traditionally managed with systemic antibiotics and occasionally requires catheter removal. Direct administration of antibiotics intra‐abdominally via peritoneal dialysis (PD) catheters is a well‐established, efficacious practice in PD‐related peritonitis and minimizes systemic adverse effects. We applied the same principles to a patient with peritoneal mesothelioma who developed peritonitis 3 weeks after insertion of IPeC. Intraperitoneal vancomycin was administered via, and compatible with, the IPeC. The patient tolerated the treatment without adverse effects and made a full recovery without requiring catheter removal.


  • Open Access

    Conservative management of a complete primary spontaneous pneumothorax

    by Thisuri Jayawardena, Sophie Krivinskas, Y. C. Gary Lee

    Large primary spontaneous pneumothorax (PSP) has traditionally been managed with needle aspiration, chest tube drainage and, in refractory cases, thoracic surgery. A recent randomized trial, however, provided evidence that a conservative observational approach was safe and 85% of patients recovered without requiring pleural drainage interventions. A conservative approach provided similar re‐expansion rates at 8 weeks compared with chest tube drainage and offered the advantages of early hospital discharge, fewer days off work and avoidance of procedural risks. Nonetheless, clinicians are understandably anxious with conservative (non‐drainage) management for patients with very large pneumothorax. Here, we report a patient with a right‐sided PSP and total lung collapse that was managed successfully without intervention with minimal time in hospital or off work.


  • Modelling the risk of transfusion‐transmitted syphilis: a reconsideration of blood donation testing strategies

    by Thisuri Jayawardena, Veronica Hoad, Claire Styles, Clive Seed, Peter Bentley, Vanessa Clifford, Sarina Lacey, Tessa Gastrell

    Background and Objectives: Donor syphilis testing began in the 1940s amidst widespread transfusion‐transmitted syphilis (TTS). Since then, the introduction of penicillin, pre‐donation screening questionnaires and improved storage conditions have contributed to reducing transmission risk. Consequently, universal testing may no longer be cost‐effective. This study analysed alternative options for donor syphilis testing to determine the optimal strategy.Materials and Methods: A model was developed using conservative parameter estimates for factors affecting TTS and 2009‐2015 Australian donations to calculate risk outcomes (TTS infections, tertiary syphilis in recipients and transfusion‐associated congenital syphilis) and cost‐effectiveness of alternative testing strategies. The strategies modelled were as follows: universal testing, targeted‐testing of high‐risk groups (males ≤50 years old and first‐time donors) and no testing.Results: The estimated risk of TTS is one in 49·5 million transfusions for universal testing, one in 6 million for targeted‐testing of males ≤50 years old, one in 4 million for targeted‐testing of first‐time donors and one in 2·8 million for no testing. For all strategies, the risk of tertiary and congenital syphilis is <1 in 100 million. Universal testing is the least cost‐effective strategy with an incremental cost‐effectiveness ratio (ICER) estimated at $538·5 million per disability‐adjusted life year averted.Conclusion: Universal testing is not required to maintain the risk of TTS within tolerable limits and is estimated to greatly exceed acceptable ICERs for blood safety interventions. However, despite a strong economic and risk‐based rationale, given the epidemiology of syphilis in Australia is changing, feedback from critical stakeholders is not currently supportive of reducing testing.